Al's Comment:
This is the new classification for brain tumors. They now recognize that GBMs with and without the IDH mutations are very different tumors - they were lumped together before, but they behave so differently that you can't compare them. All trials from now on should seperate out the data by IDH status.
For more details see iap-ad.org/lectures/ESPC/Day2/08.30%20-%2009.15%20-%20WHO-Dubai%202015.pdf
Posted on: 05/10/2016
Acta Neuropathol. 2016 May 9. [Epub ahead of print]
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Louis DN1, Perry A2, Reifenberger G3,4, von Deimling A4,5, Figarella-Branger D6, Cavenee WK7, Ohgaki H8, Wiestler OD9, Kleihues P10, Ellison DW11.
Author information:
1Department of Pathology, Massachusetts General Hospital, Harvard Medical School, WRN225, 55 Fruit Street, Boston, MA, 02114, USA. dlouis@mgh.harvard.edu.
2Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
3Department of Neuropathology, Heinrich Heine University, Duesseldorf, Germany.
4German Cancer Consortium (DKTK), Partner Site Essen/Duesseldorf, Germany.
5Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University, Heidelberg, Germany.
6Department of Pathology and Neuropathology, La Timone Hospital, Aix Marseille University, Marseille, France.
7Ludwig Institute for Cancer Research, University of California San Diego, San Diego, CA, USA.
8International Agency for Research on Cancer (IARC), Lyon, France.
9German Cancer Research Center (DKFZ), Heidelberg, Germany.
10Medical Faculty, University of Zurich, Zurich, Switzerland.
11Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Abstract
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered. The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance. Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded. Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.
PMID: 27157931 [PubMed - as supplied by publisher]
Click HERE to return to brain tumor news headlines.
